Mutual of America Capital Management LLC Grows Stock Holdings in Insmed, Inc. $INSM

Key Points

• Mutual of America Capital Management LLC increased its stake in Insmed, Inc. by 9.3% during Q2, holding 86,492 shares valued at approximately $8.7 million.
• Insmed reported a loss of $1.70 earnings per share for Q2, missing analysts’ estimates but achieving a revenue of $107.42 million, which was above expectations.
• Analysts have varied opinions on Insmed's stock, with new price targets set, including $196.00 by Goldman Sachs and an average price target of $152.88, indicating a generally favorable outlook.

Mutual of America Capital Management LLC raised its stake in Insmed, Inc. (NASDAQ:INSM - Free Report) by 9.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 86,492 shares of the biopharmaceutical company's stock after buying an additional 7,351 shares during the period. Mutual of America Capital Management LLC's holdings in Insmed were worth $8,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently added to or reduced their stakes in INSM. GAMMA Investing LLC boosted its position in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 386 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Insmed by 16.7% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 541 shares during the period. Avior Wealth Management LLC boosted its position in Insmed by 82.2% in the 1st quarter. Avior Wealth Management LLC now owns 4,151 shares of the biopharmaceutical company's stock valued at $317,000 after buying an additional 1,873 shares during the period. Whalen Wealth Management Inc. purchased a new stake in Insmed in the 1st quarter valued at about $217,000. Finally, Oppenheimer Asset Management Inc. boosted its position in Insmed by 37.7% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company's stock valued at $1,521,000 after buying an additional 5,453 shares during the period.

Insmed Stock Performance

NASDAQ INSM opened at $167.91 on Tuesday. The stock has a market capitalization of $35.49 billion, a price-to-earnings ratio of -29.41 and a beta of 1.03. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $168.22. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The stock has a 50-day moving average of $144.48 and a 200 day moving average of $105.96.

Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on INSM shares. Royal Bank Of Canada boosted their price target on shares of Insmed from $108.00 to $120.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Jefferies Financial Group boosted their price target on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a report on Wednesday, August 13th. The Goldman Sachs Group boosted their price target on shares of Insmed from $121.00 to $196.00 and gave the company a "buy" rating in a report on Friday, October 3rd. Wells Fargo & Company started coverage on shares of Insmed in a report on Monday. They issued an "overweight" rating and a $171.00 price target for the company. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Insmed in a report on Wednesday, October 8th. Nineteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $152.88.

Insider Buying and Selling

In other Insmed news, Director Melvin Md Sharoky sold 10,000 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.39, for a total transaction of $1,453,900.00. Following the transaction, the director directly owned 262,675 shares of the company's stock, valued at $38,190,318.25. This trade represents a 3.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 76,520 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $145.45, for a total transaction of $11,129,834.00. Following the transaction, the insider directly owned 36,461 shares in the company, valued at approximately $5,303,252.45. The trade was a 67.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,657 shares of company stock worth $21,442,198 in the last ninety days. 3.00% of the stock is owned by corporate insiders.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.